Atezolizumab and durvalumab (anti‐programmed cell death‐ligand 1 [PD‐L1] antibodies termed immune checkpoint inhibitors [ICIs]) were approved in August 2019 and August 2020, respectively, for the treatment of SCLC. Here, CD274 is linked to small cell lung carcinoma.